Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.57 |
| ▸ | FLT4 | P35916 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923207 | 0.86 | SLC6A3 (0.58) | ABL1FLT1FLT4KDRGAA | |
| SCHEMBL1095516 | 0.85 | MEN1 (0.64) | ABL1GAAMEN1KMT2ASLC6A4 | |
| SCHEMBL29812845 | 0.85 | MEN1 (0.64) | ABL1GAAMEN1KMT2ASLC6A4 | |
| SCHEMBL498726 | 0.83 | FLT1 (0.55) | ABL1FLT1FLT4KDRMEN1 | |
| SCHEMBL927573 | 0.83 | ALDH1A1 (0.62) | FLT1FLT4KDRMEN1KMT2A | |
| SCHEMBL1423874 | 0.83 | FLT1 (0.55) | ABL1FLT1FLT4KDRMEN1 | |
| SCHEMBL29924548 | 0.83 | FLT1 (0.55) | ABL1FLT1FLT4KDRMEN1 | |
| SCHEMBL31392274 | 0.83 | ABL1 (0.57) | ABL1FLT1FLT4KDRGAA | |
| SCHEMBL5066728 | 0.83 | LMNA (0.50) | ABL1FLT1FLT4KDRMEN1 | |
| SCHEMBL26747708 | 0.83 | ABL1 (0.57) | ABL1FLT1FLT4KDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277683-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-08-22 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-RE49575-E1 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-07-11 | — | — | US | disclosed |
| US-RE49575-E1 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-07-11 | — | — | US | disclosed |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-04-25 | — | — | US | disclosed |
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | disclosed |
| US-20210213004-A1 | Compounds | CTXT PTY LTD (AU) | 2021-07-15 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| CN-1466572-A | Pyrrole derivatives | ס����ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-5750545-A | EXHIBIT EOSINOPHIL-INHIBITORY ACTION AND LYMPHOCYTE ACTIVATION-INHIBITORY ACTION; USEFUL FOR TREATMENT OF IMMUNE-RELATED DISEASES | THE GREEN CROSS CORPORATION (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0710654-A1 | TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5238962-A | Administering an antidepressants | HOFFMANN-LA ROCHE INC. (US) | 1993-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | CHEK1, CHEK2, DDB1 | ABL1 929/4885FLT1 2822/4885FLT4 2917/4885 |
| US-20240277683-A1 | COMPOUNDS | SLC10A1, ABCB11, REN | ABL1 190/4885FLT1 4158/4885FLT4 4617/4885 |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | CHEK1, CHEK2, DDB1 | ABL1 929/4885FLT1 2822/4885FLT4 2917/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | ABL1 2293/4885FLT1 688/4885FLT4 2443/4885 |
| US-20210213004-A1 | Compounds | SLC10A1, ABCB11, REN | ABL1 364/4885FLT1 3970/4885FLT4 4631/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | ABL1 364/4885FLT1 3970/4885FLT4 4631/4885 |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | ABL1 1070/4885FLT1 2905/4885FLT4 2508/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | ABL1 2432/4885FLT1 739/4885FLT4 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.